Cullinan Therapeutics Inc - CGEM Quarterly EPS earnings growth

Corporate company logo of Cullinan Therapeutics, Inc. (CGEM)

Cullinan Therapeutics (CGEM) holds unique patents that protect its developments from competitors despite strict FDA oversight. The quarterly EPS growth rate on the GURU.Markets consolidated chart shows that the latest parameter is 10.80. However, cold chain complexities in biologic deliveries and the high intensity of R&D pipeline updates toward autoimmune pathologies create significant risks.

cullinanoncology.com (CGEM) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Cullinan Therapeutics

- share price and consensus valuation forecast:
Fundamental company valuation:cullinanoncology.com - CGEM
Flagship merchandise of cullinanoncology.com

Quarterly EPS growth reflects the dynamics of net income per share relative to previous periods. This metric is calculated by comparing operating margins and revenue growth rates to exclude the impact of one-time cost reductions. By analyzing the history of quarterly earnings per share changes, an investor determines the feasibility of business scaling. For Cullinan Therapeutics (CGEM), such a metric is critical during the development of bispecific antibodies, as it confirms the company's financial stability amidst fierce scientific competition with pharma behemoths.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Therapeutics) - Quarterly EPS earnings growth|Quarterly EPS earnings growth kymeratx.com|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences, Inc. (IDYA)|ELVN (Enliven Therapeutics, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ORIC (ORIC Pharmaceuticals Inc)|Net earnings per share growth for the trailing year Relay Pharma|Nurix Therapeutics Inc - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tyra Biosciences|VSTM (Verastem, Inc.) - Year-over-year net earnings per share growth for the last 12 months|GLUE: Year-over-year earnings per share growth rate for the last twelve months|IMRX (immuneering.com) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months C4 Tx CCCC|Quarterly EPS earnings growth BDTX|Repare Therapeutics Inc. - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Cyclacel Pharmaceuticals - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics Inc - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months glycomimetics.com GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks (SWTX)